Skip to content
In primary membranous nephropathy, obinutuzumab increased the likelihood of complete remission vs. tacrolimus at 104 wk
All contributors

Onconephrology contributor

Mirrakhimov, Aibek E

Primarily Tumor lysis & electrolytes#45 of 46 recognized
  • #5 in Tumor lysis & electrolytes
4
Clinical papers
240
Citations (iCite)
2 / 1
First / senior author
2013–2015
Active years

Output over time

Clinical corpus papers per year — peak 2 in 2014.

  • 2013: 1 paper
  • 2014: 2 papers
  • 2015: 1 paper
20132015

Subfield mix

Clinical papers by onconephrology subfield (a paper can count in more than one).

Tumor lysis & electrolytes3
Anticancer drug nephrotoxicity2

Verify

Representative recent papers, and this author’s full PubMed bibliography.

PMID 25938028 (opens PubMed in a new tab)PMID 25002953 (opens PubMed in a new tab)PMID 24772347 (opens PubMed in a new tab)PMID 23888223 (opens PubMed in a new tab)All papers on PubMed

A code-tallied bibliometric profile from PubMed + NIH iCite, restricted to human/clinical papers across a 15,541-article corpus (regenerated 2026-10-02). Recognition of published contribution — not a verdict on merit or influence, and not medical advice.